Declining incidence of Parkinson's disease in Israel (2002-2021)
- PMID: 40694141
- DOI: 10.1007/s00702-025-02984-2
Declining incidence of Parkinson's disease in Israel (2002-2021)
Abstract
The results of investigations of the trends of the incidence of Parkinson's disease (PD) over time in numerous developed countries showed that aging and increasing life expectancy are leading to an increase in both. We investigated the crude and age-adjusted incidence rates (AAIRs) of PD based upon registry data of Israel's largest health maintenance organization between 2002 and 2021 according to joinpoint regression. We applied an age-period analysis to further identify patterns of AAIR changes, and calculated longitudinal age curves of PD rates ("local drift") as well as annual change of the expected age-specific and expected age-adjusted AAIR ("net drift"). The overall AAIR of PD declined from 57 ± 1.0 to 20.3 ± 0.5 per 100,000 over 20 years, representing a 2.8-fold decrease. The PD incidence decreased more rapidly among females (average annual percent changes [AAPC] - 5.3%, 95% confidence interval [CI] - 6.0-4.6, p < 0.001) than among males (AAPC - 4.5, 95%CI - 5.3-3.7, p < 0.001). AAIRs peaked at 209.9 (CI: 193.0-228.5) per 100,000 at a median age of 77.5 vs. 374.9 (CI: 350.9-400.5) years in females and at a median age of 82.5 years in males. AAIRs gradually declined in males to 63.3 (CI: 52.2-84.1) per 100,000 and in females to 29.7 (CI: 21.4-41.1) per 100,000 for the 97.5-year-old group in both sexes. This first assessment of the trends of the incidence of PD in Israel documented its progressive decline from 2002 to 2021, especially among the very elderly. This decline may reflect refined diagnostic capabilities and enhanced health, quality of life and environmental conditions in Israel.
Keywords: Age-period analysis; Average annual percent changes; Epidemiology; Incidence; Joinpoint regression; Parkinson's disease; Time trend.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors have no conflicts of interest to declare. Ethical approval: This study was approved by the Kaplan Medical Center Institutional Review Board (protocol number: KMC-0071-22). It was based upon anonymous databases and involved no direct interaction with patients. Informed consent was not required for this study, which used anonymized data and other information which could identify the participants.
Similar articles
-
Temporal trends in the incidence of adverse effects of medical treatment in BRICS countries from 1990 to 2021: an age-period cohort analysis.Front Public Health. 2025 Jun 24;13:1508272. doi: 10.3389/fpubh.2025.1508272. eCollection 2025. Front Public Health. 2025. PMID: 40630400 Free PMC article.
-
Incidence and disability-adjusted life-years of infective endocarditis in China from 1990 to 2021: comparison with G20 based on the Global Burden of Disease Study 2021.BMJ Open. 2025 Jul 6;15(7):e094490. doi: 10.1136/bmjopen-2024-094490. BMJ Open. 2025. PMID: 40623737 Free PMC article.
-
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Mar 27;3:CD009885. doi: 10.1002/14651858.CD009885.pub3. PMID: 26599576 Free PMC article. Updated.
-
Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.J Parkinsons Dis. 2024;14(7):1405-1416. doi: 10.3233/JPD-240115. J Parkinsons Dis. 2024. PMID: 39240648 Free PMC article.
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
References
-
- Agoriwo MW, Joseph C, Franzén E, Unger M (2024) Assessing the factors that influence the utilization and delivery of rehabilitation services among persons with parkinson’s disease: a scoping review. J Eval Clin Pract 30(6):873–886. https://doi.org/10.1111/jep.13999 - DOI - PubMed
-
- Ahmad OE, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M (2000) Age standardization of rates: a new WHO standard GPE discussion paper series. World Health Organization, Geneva
-
- Atterling Brolin K, Schaeffer E, Kuri A, Rumrich IK, Schumacher Schuh AF, Darweesh SKL, Kaasinen V, Tolppanen AM, Chahine LM, Noyce AJ (2025) Environmental risk factors for parkinson’s disease: a critical review and policy implications. Mov Disord 40(2):204–221. https://doi.org/10.1002/mds.30067 - DOI - PubMed
-
- Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C (2024) The epidemiology of parkinson’s disease. Lancet 403(10423):283–292. https://doi.org/10.1016/S0140-6736(23)01419-8 - DOI - PubMed - PMC
-
- Bianchi VE, Rizzi L, Somaa F (2023) The role of nutrition on parkinson’s disease: a systematic review. Nutr Neurosci 26(7):605–628. https://doi.org/10.1080/1028415X.2022.2073107 - DOI - PubMed
LinkOut - more resources
Full Text Sources